Thermo Fisher’s Oncomine obtains FDA approval as CDx for lung cancer drug
The Oncomine Dx Target Test is designed to simultaneously assess 23 genes associated with NSCLC.

The Oncomine Dx Target Test is designed to simultaneously assess 23 genes associated with NSCLC.
Abbott's i-STAT TBI Plasma test and ARCHITECT core laboratory instrument were used to measure the two biomarkers.
Paige will provide Sonora Quest Laboratories with Paige Breast, Paige Prostate Detect and its FullFocus viewer.
The test can be integrated into electronic health records to help clinicians counsel patients.
Empyrean and MD Anderson will combine their expertise to improve radiation therapy delivery for cancer patients.
To better identify early-onset cancer, the researchers eliminated the miRNA markers shared by early-onset and late-onset patients.
The new device can be integrated with a smartwatch and continuously monitors biosignals.
The companies will combine their capabilities to advance flow cytometry as an essential CDx modality for cancer.
Thank you for subscribing to Medical Device Network